A combination of ceftaroline and daptomycin has synergistic and bactericidal activity in vitro against daptomycin nonsusceptible methicillin-resistant Staphylococcus aureus (MRSA)

References

• Hawkins C, Huang J, Jin N, et al. Persistent Staphylococcus aureus bacteremia: an analysis of risk factors and outcomes. Arch Intern Med. 2007;167:1861–1867.
   PubMedGoogle Scholar
• Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52:285–292.
   PubMed Web of Science ®Google Scholar
• Estabrook M, Bussell B, Clugston SL, et al. In vitro activity of ceftolozane–tazobactam as determined by broth dilution and agar diffusion assays against recent US Escherichia coli isolates from 2010 to 2011 carrying CTX-M-type extended-spectrum beta-lactamases. J Clin Microbiol. 2014;52:4049–4052.
   PubMed Web of Science ®Google Scholar
• Laudano JB. Ceftaroline fosamil: a new broad-spectrum cephalosporin. J Antimicrob Chemother. 2011;66(Suppl 3):iii11–iii18.
   PubMed Web of Science ®Google Scholar
• Sader HS, Farrell DJ, Flamm RK, et al. Activity of ceftaroline and comparator agents tested against Staphylococcus aureus from patients with bloodstream infections in US medical centres (2009-13). J Antimicrob Chemother. 2015;70:2053–2056.
   PubMed Web of Science ®Google Scholar
• Alm RA, McLaughlin RE, Kos VN, et al. Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: an epidemiological and structural perspective. J Antimicrob Chemother. 2014;69:2065–2075.
   PubMed Web of Science ®Google Scholar
• Farha MA, Leung A, Sewell EW, et al. Inhibition of WTA synthesis blocks the cooperative action of PBPs and sensitizes MRSA to β-lactams. ACS Chem Biol. 2013;8:226–233.
   PubMed Web of Science ®Google Scholar
• Dhand A, Bayer AS, Pogliano J, et al. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis. 2011;53:158–163.
   PubMed Web of Science ®Google Scholar
• Berti AD, Sakoulas G, Nizet V, et al. Beta-lactam antibiotics targeting PBP1 selectively enhance daptomycin activity against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2013;57:5005–5012.
   PubMed Web of Science ®Google Scholar
• CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fifth Informational Supplement. CLSI document M100-S25. Wayne, PA: Clinical and Laboratory Standards Institute; 2015.
   Google Scholar
• Barber KE, Werth BJ, McRoberts JP, et al. A novel approach utilizing biofilm time-kill curves to assess the bactericidal activity of ceftaroline combinations against biofilm-producing methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2014;58:2989–2992.
   PubMed Web of Science ®Google Scholar
• Kullar R, McKinnell JA, Sakoulas G. Avoiding the perfect storm: the biologic and clinical case for reevaluating the 7-day expectation for methicillin-resistant Staphylococcus aureus bacteremia before switching therapy. Clin Infect Dis. 2014;59:1455–1461.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Nicco E, Ginocchio F, et al. High-dose daptomycin in documented Staphylococcus aureus infections. Int J Antimicrob Agents. 2010;36:459–461.
   PubMed Web of Science ®Google Scholar
• Carugati M, Bayer AS, Miró JM, et al. High-dose daptomycin therapy for left-sided infective endocarditis. A prospective study from the international collaboration on endocarditis (ICE). Antimicrob Agents Chemother. 2013;57:6213–6222.
   Google Scholar
• Kullar R, Davis SL, Levine DP, et al. High‐dose daptomycin for treatment of complicated gram‐positive infections: a large, multicenter, retrospective study. Pharmacotherapy. 2011;31:527–536.
   PubMed Web of Science ®Google Scholar
• Rose WE, Leonard SN, Rybak MJ. Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother. 2008;52:3061–3067.
   PubMed Web of Science ®Google Scholar
• Canut A, Isla A, Rodriguez-Gascon A. Pharmacokinetic/pharmacodynamic analysis to evaluate ceftaroline fosamil dosing regimens for the treatment of community-acquired bacterial pneumonia and complicated skin and skin–structure infections in patients with normal and impaired renal function. Int J Antimicrob Agents. 2015;45:399–405.
   PubMed Web of Science ®Google Scholar
• Ho TT, Cadena J, Childs LM, et al. Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy. J Antimicrob Chemother. 2012;67:1267–1270.
   PubMed Web of Science ®Google Scholar
• Fabre V, Ferrada M, Buckel WR, et al. Ceftaroline in combination with trimethoprim–sulfamethoxazole for salvage therapy of methicillin-resistant Staphylococcus aureus bacteremia and endocarditis. Open Forum Infect Dis. 2014;1:ofu046.
   PubMedGoogle Scholar
• Sakoulas G, Moise PA, Casapao AM, et al. Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline. Clin Ther. 2014;36:1317–1333.
   PubMed Web of Science ®Google Scholar
• Barber KE, Rybak MJ, Sakoulas G. Vancomycin plus ceftaroline shows potent in vitro synergy and was successfully utilized to clear persistent daptomycin-non-susceptible MRSA bacteraemia. J Antimicrob Chemother. 2015;70:311–313.
   PubMed Web of Science ®Google Scholar
• Barber KE, Ireland CE, Bukavyn N, et al. Observation of “seesaw effect” with vancomycin, teicoplanin, daptomycin and ceftaroline in 150 unique MRSA strains. Infect Dis Ther. 2014;3:35–43.
   PubMedGoogle Scholar
• Yang SJ, Xiong YQ, Boyle-Vavra S, et al. Daptomycin–oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the "seesaw effect"). Antimicrob Agents Chemother. 2010;54:3161–3169.
   PubMed Web of Science ®Google Scholar
• Rose WE, Schulz LT, Andes D, et al. Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity. Antimicrob Agents Chemother. 2012;56:5296–5302.
   PubMed Web of Science ®Google Scholar
• Sakoulas G, Rose W, Nonejuie P, et al. Ceftaroline restores daptomycin activity against daptomycin-nonsusceptible vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother. 2014;58:1494–1500.
   PubMed Web of Science ®Google Scholar